It’s been a long hard slog for LBT, this will help. Open for discussion…I’ve always thought a pay per service was a better business model I.e. per culture plate read rather than selling the whole module at huge expense.
Is the cost of the module a barrier to purchase? Would a fee per plate read and a leasing of equipment fee open up more markets? Thoughts anyone?
Ann: AstraZeneca Partners LBT for APAS Pharma Development, page-9
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
-0.002(11.8%) |
Mkt cap ! $23.31M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.6¢ | 1.4¢ | $66.59K | 4.467M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 486857 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 702681 | 1 |
View Market Depth
| Last trade - 15.53pm 28/06/2024 (20 minute delay) ? |
| LBT (ASX) Chart |